Evaluate possibility of allergic reactions in persons sensitive to the components of the vaccine. Do not administer intravascularly, intradermally, SC, or into the buttocks. Not to be used for treatment of disease caused by
Bordetella pertussis,
Corynebacterium diphtheriae,
Clostridium tetani or poliomyelitis infections. Not to be given in fractional doses (<0.5 mL). Possible syncope; place procedures to prevent falling injury & manage syncopal reactions. May not protect 100% of vaccinated persons. Postpone vaccination in case of an acute or febrile disease. Possible inj site hematoma in persons w/ any bleeding disorders (eg, haemophilia or thrombocytopenia) or in persons on anticoagulant therapy. Consider delaying vaccination until after the completion of any immunosuppressive treatment in immunocompromised persons if possible; vaccination of persons w/ chronic immunodeficiency (eg, HIV) is recommended even if immune response might be limited. Not to be administered to individuals w/ progressive neurological disorder, uncontrolled epilepsy or progressive encephalopathy until treatment regimen has been established & condition has stabilized. Carefully consider use if Guillain-Barré syndrome occurred w/in 6 wk of receipt of prior tetanus-toxoid containing vaccine. Pregnancy; may be administered during 2nd or 3rd trimester. Lactation.
Sign Out
